Vorinostat

  • #LGM Pharma is a Vorinostat CAS# 149647-78-9 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 149647-78-9
  • AHFC code:
  • Synonyms: MK0683 N-hydroxy-n'-phenyloctanediamide N-hyrdroxy-n'-phenyloctanediamide SAHA SHH Suberanilohydroxamic acid suberoylanilide hydroxamic acid
  • ATC Code: L01XX38
  • Chemical Formula: C19H16O4
  • Molecular Weight: 264.3202
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB02546 (EXPT02902)
  • SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
  • InChl: WAEXFXRVDQXREF-UHFFFAOYSA-N
  • PubChem: 5311
  • IUPAC: N-hydroxy-N'-phenyloctanediamide

Additional Details

Indication:
For the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.
Pharmacodynamics:
Mode of Action:
Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC5_
Metabolism:
The major pathways of vorinostat metabolism involve glucuronidation and hydrolysis followed by _-oxidation. Human serum levels of two metabolites, O-glucuronide of vorinostat and 4-anilino-4-oxobutanoic acid were measured. Both metabolites are pharmacologically inactive. Compared to vorinostat, the mean steady state serum exposures in humans of the O-glucuronide of vorinostat and 4-anilino-4-oxobutanoic acid were 4-fold and 13-fold higher, respectively. In vitro studies using human liver microsomes indicate negligible biotransformation by cytochromes P450 (CYP).
Toxicity:
General Reference:
Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE: Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther. 2006 Aug;5(8):1967-74. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos